PHARMACOECONOMICAL APPROVAL OF GENOTYPING ELIGIBILITY IN PATIENTS WITH DIABETES MELLITUS TYPE 2 TAKING METFORMIN

Abstract

Effectiveness of sugar-lowering therapy depends on both betimes started therapy and genetically defined features of a patient. Single nucleotide polymorphism of genes may be perspective and approved by pharmacoeconomical analyses. We observed 89 patients with newly diagnosed diabetes mellitus type 2 and 80 subjects without impaired glucose metabolism. We found out 2 types of patients- with “response phenotype“ and “fail phenotype”. CER showed that genotyping before prescribing metformin in order to find out “fail phenotype” to avoid lack of effectiveness could reduce expenses.

Keywords

• metformin
• diabetes mellitus type 2
• pharmcoeconomical analyses
• personified therapy